MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ohn.70390

Медицинская библиотека · Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026

Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab.

Walker Kendra, Valencia-Sanchez Bastien A, Wilson Prishae, Najmi Natasha, Donaldson Angela M

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Rituximab causes B-cell depletion and hypogammaglobulinemia, increasing risk for infections. This study aims to determine the incidence of chronic rhinosinusitis (CRS) in patients following rituximab therapy.

STUDY

DESIGN

Retrospective cohort study using chart review of patients prescribed rituximab between January 2019 and January 2025.

SETTING

Multisite study across Mayo Clinic Enterprise locations in Arizona, Florida, Minnesota, and Wisconsin.

METHODS

Patients with documented rituximab use were included; those with pre-existing CRS were excluded. Demographic and clinical data-including timing and duration of rituximab therapy, CRS diagnosis, comorbidities (asthma, allergic rhinitis, GERD), and need for sinus surgery-were collected. Descriptive statistics summarized patient characteristics. Group comparisons were performed using t-tests, Mann-Whitney U, and chi-square tests. Analyses were conducted using SPSS v28.

RESULTS

Among 17,851 patients prescribed rituximab (median age 64.0 years, M:F ratio 1.1:1), 1105 (6.2%) developed CRS, with an annual incidence of 1.03% (1032 cases per 100,000 person-years). The median duration of rituximab therapy for those diagnosed with CRS was 5.9 months (IQR, 0.5-42.6). Most CRS cases occurred after rituximab discontinuation (62.7%, n = 693) compared to during active treatment (37.3%, n = 412). The median delay between rituximab discontinuation and CRS diagnosis was 17.0 months (IQR, 4.3-41.7).

CONCLUSIONS

This study demonstrates an annual incidence of 1.03% for CRS diagnoses following rituximab. While prior studies report varying CRS incidences in the general population (0.25%-0.73%), our findings suggest increased risk among rituximab users. Most CRS diagnoses occurred after rituximab discontinuation, emphasizing the need for a comprehensive medication history review during CRS evaluation.

Для цитирования: Walker Kendra, Valencia-Sanchez Bastien A, Wilson Prishae, Najmi Natasha, Donaldson Angela M. Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2026. DOI: 10.1002/ohn.70390.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.